{"id":"ag221","safety":{"commonSideEffects":[{"rate":"34%","effect":"Fatigue"},{"rate":"24%","effect":"Nausea"},{"rate":"21%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3989908","moleculeType":"Small molecule","molecularWeight":"473.38"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AG221 is an inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme, which is mutated in certain types of leukemia.","oneSentence":"IDH2 inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:51:22.359Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT06672146","phase":"PHASE2","title":"Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-16","conditions":"Acute Myeloid Leukemia","enrollment":93},{"nctId":"NCT06577441","phase":"PHASE2","title":"Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-12","conditions":"Myelodysplastic Syndrome","enrollment":54},{"nctId":"NCT05756777","phase":"PHASE1","title":"A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-06-26","conditions":"Acute Myeloid Leukemia (AML)","enrollment":18},{"nctId":"NCT03728335","phase":"PHASE2","title":"Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-07-11","conditions":"Acute Myeloid Leukemia","enrollment":35},{"nctId":"NCT03683433","phase":"PHASE2","title":"Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-09-18","conditions":"Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Chronic Myelomonocytic Leukemia","enrollment":50},{"nctId":"NCT02677922","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-06-03","conditions":"Leukemia, Myeloid, Acute","enrollment":130},{"nctId":"NCT03383575","phase":"PHASE2","title":"Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-01-17","conditions":"Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia","enrollment":63},{"nctId":"NCT06240754","phase":"PHASE2","title":"Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-10-10","conditions":"Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance","enrollment":15},{"nctId":"NCT05102370","phase":"PHASE1","title":"A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-10-06","conditions":"Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance","enrollment":4},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT05010772","phase":"PHASE1","title":"Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-25","conditions":"Acute Myeloid Leukemia","enrollment":125},{"nctId":"NCT04203316","phase":"PHASE2","title":"Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-08-14","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":1},{"nctId":"NCT06756308","phase":"PHASE2","title":"A Study of Enasidenib in People With T-Cell Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-12-24","conditions":"T-cell Lymphoma","enrollment":25},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT04774393","phase":"PHASE1, PHASE2","title":"Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-24","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":84},{"nctId":"NCT06176989","phase":"PHASE2","title":"Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-03-04","conditions":"Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma, Metastatic Sinonasal Adenocarcinoma","enrollment":40},{"nctId":"NCT03515512","phase":"PHASE1","title":"IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-07-17","conditions":"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":23},{"nctId":"NCT05441514","phase":"PHASE1","title":"Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-11-03","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":3},{"nctId":"NCT04822766","phase":"NA","title":"A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-31","conditions":"Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT03680677","phase":"","title":"Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2018-09-21","conditions":"Leukemia, Acute, MDS","enrollment":20},{"nctId":"NCT04603001","phase":"PHASE1","title":"Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-11-19","conditions":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)","enrollment":260},{"nctId":"NCT03744390","phase":"PHASE2","title":"IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2019-04-02","conditions":"Myelodysplastic Syndromes, Leukemia Acute Myeloid","enrollment":68},{"nctId":"NCT02577406","phase":"PHASE3","title":"An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-12-30","conditions":"Leukemia, Myeloid, Isocitrate Dehydrogenase","enrollment":319},{"nctId":"NCT05401097","phase":"PHASE2","title":"IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)","status":"RECRUITING","sponsor":"Alice Mims","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":125},{"nctId":"NCT02632708","phase":"PHASE1","title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2015-12-31","conditions":"Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS)","enrollment":153},{"nctId":"NCT05282459","phase":"PHASE1, PHASE2","title":"Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation","status":"COMPLETED","sponsor":"Stanford University","startDate":"2022-01-12","conditions":"Leukemia, Leukemia, Myeloid, Monocytic Leukemia","enrollment":17},{"nctId":"NCT03732703","phase":"PHASE1, PHASE2","title":"Myeloma-Developing Regimens Using Genomics (MyDRUG)","status":"COMPLETED","sponsor":"Multiple Myeloma Research Consortium","startDate":"2019-04-01","conditions":"Relapsed Refractory Multiple Myeloma","enrollment":103},{"nctId":"NCT04281498","phase":"PHASE2","title":"Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation","status":"COMPLETED","sponsor":"John Mascarenhas","startDate":"2021-01-14","conditions":"Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation","enrollment":6},{"nctId":"NCT01915498","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation","status":"COMPLETED","sponsor":"Celgene","startDate":"2013-08-27","conditions":"Hematologic Neoplasms","enrollment":345},{"nctId":"NCT03839771","phase":"PHASE3","title":"A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2019-03-01","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2","enrollment":968},{"nctId":"NCT04522895","phase":"PHASE2","title":"IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2020-08-27","conditions":"Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia","enrollment":50},{"nctId":"NCT04955938","phase":"PHASE1","title":"A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2021-10-29","conditions":"IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation","enrollment":""},{"nctId":"NCT04573582","phase":"PHASE1","title":"Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment","status":"COMPLETED","sponsor":"Celgene","startDate":"2020-11-13","conditions":"Hepatic Impairment","enrollment":40},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT03720366","phase":"PHASE1","title":"A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-10-04","conditions":"Leukemia, Myeloid, Acute","enrollment":40},{"nctId":"NCT04092179","phase":"PHASE1, PHASE2","title":"Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers","status":"TERMINATED","sponsor":"University Health Network, Toronto","startDate":"2020-11-05","conditions":"Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer","enrollment":27},{"nctId":"NCT04075747","phase":"PHASE1","title":"A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2019-12-02","conditions":"Acute Myeloid Leukemia","enrollment":57},{"nctId":"NCT03825796","phase":"PHASE2","title":"CPX-351 Plus Enasidenib for Relapsed AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-04-12","conditions":"Recurrent Acute Myeloid Leukemia","enrollment":2},{"nctId":"NCT02665065","phase":"PHASE3","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2016-06","conditions":"Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute","enrollment":153},{"nctId":"NCT04655391","phase":"PHASE1","title":"Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2022-06-25","conditions":"Recurrent Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT03881735","phase":"PHASE2","title":"Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation","status":"WITHDRAWN","sponsor":"Roswell Park Cancer Institute","startDate":"2019-12-02","conditions":"Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level, IDH2 Gene Mutation","enrollment":""},{"nctId":"NCT02273739","phase":"PHASE1, PHASE2","title":"Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-12-08","conditions":"Solid Tumor, Glioma, Angioimmunoblastic T-cell Lymphoma","enrollment":21},{"nctId":"NCT03290443","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-09-21","conditions":"Hepatic Impairment","enrollment":31},{"nctId":"NCT04310527","phase":"PHASE1","title":"Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults","status":"COMPLETED","sponsor":"Celgene","startDate":"2019-10-09","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT03723057","phase":"","title":"Expanded Access for AG-221","status":"NO_LONGER_AVAILABLE","sponsor":"Celgene","startDate":"","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT02443168","phase":"PHASE1","title":"Radiolabeled Study of AG-221 in Healthy Male Subjects.","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-05-14","conditions":"Healthy Volunteers","enrollment":8},{"nctId":"NCT02387866","phase":"PHASE1","title":"PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-03-02","conditions":"Healthy","enrollment":62},{"nctId":"NCT02218346","phase":"PHASE1","title":"Food Effect Study of AG-221 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Agios Pharmaceuticals, Inc.","startDate":"2014-08","conditions":"Healthy Volunteers","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AG221","genericName":"AG221","companyName":"Agios Pharmaceuticals, Inc.","companyId":"agios-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IDH2 inhibitor Used for Acute myeloid leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}